GuidelineArthritis & rheumatology (Hoboken, N.J.)2022
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease.
Guideline in Arthritis & rheumatology (Hoboken, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 33 citations in OpenAlex.
- Ultrasound evaluation of pediatric lymphadenopathies: diagnostic patterns and pitfalls.Pediatric radiology · 2026Review
- Tocilizumab for the Treatment of Intravenous Immunoglobulin-Resistant Kawasaki Disease in Children: Two Case Reports and Literature Review.Journal of inflammation research · 2026Article
- Development and validation of a cytokine-based diagnostic model for Kikuchi-Fujimoto disease.Frontiers in immunology · 2026Article
- Refractory Kawasaki Disease in Infants Complicated with Giant Coronary Artery Aneurysms and Takayasu Arteritis: A Rare Case Report and Literature Review.Vascular health and risk management · 2026Review
- Dynamic assessment of myocardial contractile dysfunction and its recovery after IVIG treatment in a murine model of Kawasaki disease using high-resolution speckle-tracking echocardiography.Frontiers in cardiovascular medicine · 2026Article
- Novel risk scoring system for predicting intravenous immunoglobulin resistance and coronary artery aneurysm in Thai children with Kawasaki disease.Pediatric rheumatology online journal · 2025Article
- Explainable deep learning algorithm for distinguishing IVIG-Resistant Kawasaki disease in Shandong peninsula, China.BMC pediatrics · 2025Article
- Navigating the 2024 AHA guidelines for Kawasaki disease: practical insights for clinicians.World journal of pediatrics : WJP · 2025Article
- Contemporary Diagnosis, Management, and Early Outcomes in Children with Kawasaki Disease in Romania: A Single-Center Experience.Diagnostics (Basel, Switzerland) · 2025Article
- Article
- The clinical manifestation and diagnostic features of Kawasaki-like phenotypes in pediatric multisystem inflammatory syndrome: a comparative retrospective study in Ukraine.Frontiers in pediatrics · 2025Article
- Analysis and validation of clinical subgroups of Kawasaki disease in children in China: a retrospective study.BMJ paediatrics open · 2024Article
- Knowledge framework of intravenous immunoglobulin resistance in the field of Kawasaki disease: A bibliometric analysis (1997-2023).Immunity, inflammation and disease · 2024Article
- Involvement of IL-17 A/IL-17 Receptor A with Neutrophil Recruitment and the Severity of Coronary Arteritis in Kawasaki Disease.Journal of clinical immunology · 2024Article
- Exploring the diagnostic value of CLR and CPR in differentiating Kawasaki disease from other infectious diseases based on clinical predictive modeling.Frontiers in pediatrics · 2024Article
- The expression of autophagy markers in IVIG-resistant Kawasaki disease and the establishment of prediction model.BMC pediatrics · 2023Article
- Dilemma in diagnosing incomplete Kawasaki disease in a resource limited setting.Annals of medicine and surgery (2012) · 2023Article
- Predictors and a novel predictive model for intravascular immunoglobulin resistance in Kawasaki disease.Italian journal of pediatrics · 2023Article
- Kawasaki disease complicated with shock syndrome, macrophage activation syndrome, and acute abdomen in children: Two case reports.Frontiers in pediatrics · 2023Article
- Case report: Giant coronary artery aneurysms with severe stenosis and multiple abdominal artery aneurysms.Frontiers in medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
41 authors at 20 institutions in 2 countries.
Funding
Abstract
objectiveTo provide evidence-based recommendations and expert guidance for the management of Kawasaki disease (KD), focusing on clinical scenarios more commonly addressed by rheumatologists.
methodsSixteen clinical questions regarding diagnostic testing, treatment, and management of KD were developed in the Patient/Population, Intervention, Comparison, and Outcomes (PICO) question format. Systematic literature reviews were conducted for each PICO question. We used the Grading of Recommendations, Assessment, Development and Evaluation method to assess the quality of evidence and formulate recommendations. Each recommendation required consensus from at least 70% of the Voting Panel.
resultsWe present 1 good practice statement, 11 recommendations, and 1 ungraded position statement to guide the management of KD and clinical scenarios of suspected KD. These recommendations for KD are focused on situations in which input from rheumatologists may be requested by other managing specialists, such as in cases of treatment-refractory, severe, or complicated KD. The good practice statement affirms that all patients with KD should receive initial treatment with intravenous immunoglobulin (IVIG). In addition, we developed 7 strong and 4 conditional recommendations for the management of KD or suspected KD. Strong recommendations include prompt treatment of incomplete KD, treatment with aspirin, and obtaining an echocardiogram in the setting of unexplained macrophage activation syndrome or shock. Conditional recommendations include use of IVIG with other adjuvant agents for patients with KD and high-risk features of IVIG resistance and/or coronary artery aneurysms. These recommendations endorse minimizing risk to the patient by using established therapy promptly at disease onset and identifying situations in which adjunctive therapy may be warranted.
conclusionThese recommendations provide guidance regarding diagnostic strategies, use of pharmacologic agents, and use of echocardiography in patients with suspected or confirmed KD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.